Illumina stock tumbled Thursday after the genetics company finished its $8 billion acquisition of Grail despite an ongoing investigation by European regulators.
XEvercore ISI analyst Vijay Kumar called it a “maverick move.” Canaccord Genuity analyst Kyle…
